Application of droplet digital PCR – the assessment of plasma KRAS status in patients with a high risk of pancreatic cancer
Annotation: Pancreatic cancer (PanCa) has one of the lowest 5-year survival rates. To improve the prognosis of PanCa, it is necessary to develop tools that will enable earlier diagnosis. Recently, attention has been focused on liquid biopsy, which can noninvasively reflect the whole genetic profile of the tumour. Our study aims to discover whether KRAS gene mutations can be detected in the plasma DNA isolated from the PanCa risk group patients (patients with diabetes mellitus II and chronic pancreatitis) using droplet digital PCR.
The seminar will be held in person on Thursday, 6th April 2023, at 2:00 p.m. in the Turquoise Auditorium of the IEM CAS. The invitation with a short annotation you can find in the attachment.
We are looking forward to your participation.